Al Benson

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. doi request reprint Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis
    Polina Khrizman
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 66011, USA
    J Clin Oncol 31:30-8. 2013
  2. doi request reprint Effect of the accountable care act of 2010 on clinical trial insurance coverage
    Sheetal M Kircher
    Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    J Clin Oncol 30:548-53. 2012
  3. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
  4. ncbi request reprint Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients
    A B Benson
    Department of Medicine, Northwestern University Medical School, and Robert H Lurie Comprehensive Cancer Center Chicago, Illinois 60611, USA
    Clin Cancer Res 6:3870-7. 2000
  5. ncbi request reprint ZD9331 in combination with topotecan: phase I and II experience
    Al Benson
    Northwestern University Feinberg School of Medicine, Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Anticancer Drugs 14:S21-7. 2003
  6. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease
    Al B Benson
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 13:6913s-20s. 2007
  7. ncbi request reprint Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    Al B Benson
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 22:2918-26. 2004
  8. ncbi request reprint Epidemiology, disease progression, and economic burden of colorectal cancer
    Al B Benson
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Manag Care Pharm 13:S5-18. 2007
  9. ncbi request reprint New approaches to the adjuvant therapy of colon cancer
    Al B Benson
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Division of Hematology Oncology, 676 N St Clair, Suite 850, Chicago, Illinois 60611, USA
    Oncologist 11:973-80. 2006
  10. ncbi request reprint Future directions in adjuvant therapy for rectal cancer
    Al B Benson
    Clinical Investigations Program, Northwestern University Medical School, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 16:45-51. 2002

Detail Information

Publications89

  1. doi request reprint Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis
    Polina Khrizman
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 66011, USA
    J Clin Oncol 31:30-8. 2013
    ..Practice guidelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging...
  2. doi request reprint Effect of the accountable care act of 2010 on clinical trial insurance coverage
    Sheetal M Kircher
    Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    J Clin Oncol 30:548-53. 2012
    ..Currently, there are states that already have laws or agreements requiring clinical trial coverage, but there remain deficiencies that will need to be addressed to achieve compliance with the new law...
  3. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
    ..As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA...
  4. ncbi request reprint Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients
    A B Benson
    Department of Medicine, Northwestern University Medical School, and Robert H Lurie Comprehensive Cancer Center Chicago, Illinois 60611, USA
    Clin Cancer Res 6:3870-7. 2000
    ..Further investigation of dose/schedule and biological end points is ongoing...
  5. ncbi request reprint ZD9331 in combination with topotecan: phase I and II experience
    Al Benson
    Northwestern University Feinberg School of Medicine, Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Anticancer Drugs 14:S21-7. 2003
    ....
  6. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease
    Al B Benson
    Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 13:6913s-20s. 2007
    ..E5204 is the adjuvant comparison of FOLFOX with or without bevacizumab and is also available to NSABP R-04 patients...
  7. ncbi request reprint Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    Al B Benson
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 22:2918-26. 2004
    ..To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea...
  8. ncbi request reprint Epidemiology, disease progression, and economic burden of colorectal cancer
    Al B Benson
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Manag Care Pharm 13:S5-18. 2007
    ..The 5-year mortality for people diagnosed with CRC is approximately 40%; however, survival improves substantially if the cancer is diagnosed while still localized...
  9. ncbi request reprint New approaches to the adjuvant therapy of colon cancer
    Al B Benson
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Division of Hematology Oncology, 676 N St Clair, Suite 850, Chicago, Illinois 60611, USA
    Oncologist 11:973-80. 2006
    ..Incorporation of molecular markers in the design of current trials may enable us to refine our identification of patients at highest risk of recurrence and hence those standing to gain most from adjuvant therapy...
  10. ncbi request reprint Future directions in adjuvant therapy for rectal cancer
    Al B Benson
    Clinical Investigations Program, Northwestern University Medical School, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 16:45-51. 2002
    ..In addition, prospective evaluation of laboratory correlates, including molecular markers, will be integrated into trial design...
  11. ncbi request reprint Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
    A B Benson
    Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    Ann Oncol 13:576-81. 2002
    ..The purpose of this study was to evaluate the safety and efficacy of eniluracil/5-fluorouracil (5-FU) in the treatment of patients with this highly refractory disease...
  12. ncbi request reprint Oral eniluracil/5-FU for advanced colon and breast carcinomas
    A B Benson
    Division of Hematology Oncology, Department of Medicine, Clinical Investigations Program, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 15:57-63; discussion 64. 2001
    ..The phase I trials have demonstrated limited toxicities including diarrhea, mucositis, and neutropenia. Follow-up clinical trials have targeted colon and breast cancers in particular...
  13. doi request reprint Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres
    Mary F Mulcahy
    Department of Medicine, Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Cancer 115:1849-58. 2009
    ..The objective of the current study was to determine the safety and efficacy of Yttrium-90 (Y90) microsphere treatment in patients with liver-dominant colorectal metastases...
  14. doi request reprint Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival
    Kent T Sato
    Department of Radiology, Section of Interventional Radiology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N Saint Clair St, Suite 800, Chicago, IL 60611, USA
    Radiology 247:507-15. 2008
    ..To prospectively evaluate the safety, efficacy, and survival of patients with chemorefractory liver metastases who have been treated with yttrium 90 ((90)Y) glass microspheres...
  15. doi request reprint Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study
    Saad M Ibrahim
    Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer 113:2119-28. 2008
    ..The objective of this report was to present data from an open-label cohort study in which patients with intrahepatic cholangiocarcinoma (ICC) underwent radioembolization with yttrium-90 ((90)Y) microspheres...
  16. ncbi request reprint Adjuvant therapy in stage II colon cancer: current approaches
    Lisa Baddi
    Northwestern University, Division of Hematology Oncology, 676 North St Clair, Suite 850, Chicago, Illinois 60611, USA
    Oncologist 10:325-31. 2005
  17. ncbi request reprint Adjuvant chemotherapy of stage III colon cancer
    Al B Benson
    Division of Hematology Oncology, Feinburg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 32:S74-7. 2005
    ..Ongoing studies are likely to provide information that will markedly improve the ability to select optimal adjuvant therapy for individual patients...
  18. ncbi request reprint Panitumumab in metastatic colorectal cancer
    Kari B Wisinski
    Robert H Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Ill, USA
    Clin Adv Hematol Oncol 5:10-1. 2007
  19. ncbi request reprint Adjuvant therapy for colon cancer
    Olivia Aranha
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Division of Hematology Oncology, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Gastroenterol Rep 9:415-21. 2007
    ..The current Intergroup study stratifying stage II patients based on presence of microsatellite instability and loss of heterozygosity 18q allele will help us better understand the risk versus benefit observed...
  20. doi request reprint Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial
    William Small
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, 251 East Huron St, LC 178, Chicago, IL 60611, USA
    J Clin Oncol 26:942-7. 2008
    ..This study assessed safety and efficacy of full-dose gemcitabine administered before and during concurrent three-dimensional conformal radiation (3D-CRT) in patients with nonmetastatic pancreatic cancer...
  21. ncbi request reprint Chemotherapy-induced mucositis: focusing on diarrhea
    Kari Wisinski
    Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Support Oncol 5:270-1. 2007
  22. ncbi request reprint The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
    Mario E Lacouture
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Support Oncol 4:236-8. 2006
  23. pmc Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort
    Robert J Lewandowski
    Dept of Radiology, Section of Interventional Radiology, Robert H Lurie Comprehensive Cancer Ctr, Northwestern Memorial Hosp, 676 N St Clair St, Suite 800, Chicago, IL 60611, USA
    Radiology 255:955-65. 2010
    ..To determine comprehensive imaging and long-term survival outcome following chemoembolization for hepatocellular carcinoma (HCC)...
  24. doi request reprint Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival
    Ahsun Riaz
    Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 27:5734-42. 2009
    ..We present a novel correlation of AFP response to radiologic response, time-to-progression (TTP), progression-free survival (PFS), and overall survival (OS) in patients treated with locoregional therapies...
  25. doi request reprint Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes
    Riad Salem
    Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Chicago, Illinois 60611, USA
    Gastroenterology 138:52-64. 2010
    ..Hepatocellular carcinoma (HCC) has limited treatment options; long-term outcomes following intra-arterial radiation are unknown. We assessed clinical outcomes of patients treated with intra-arterial yttrium-90 microspheres (Y90)...
  26. ncbi request reprint Pre- and postoperative adjuvant therapy for locally advanced rectal cancer
    Laura P McGartland
    Department of Medicine, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Adv Hematol Oncol 2:806-14. 2004
    ..Continued emphasis on improving survival, decreasing local recurrence, and minimizing treatment toxicity to improve quality of life are the goals of ongoing research in the field of rectal cancer...
  27. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  28. ncbi request reprint Bevacizumab in the treatment of colorectal cancer
    Jeffrey C Cilley
    Northwestern University, 676 North Saint Clair, Suite 21 100, Chicago, IL 60611, USA
    Expert Opin Biol Ther 7:739-49. 2007
    ..Existing treatment and research strategies are examining its use in the adjuvant setting or in combination with other angiogenesis inhibitors...
  29. ncbi request reprint Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers
    Charles L Bennett
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Arch Intern Med 167:1041-9. 2007
    ..We compare safety efforts for evaluating serious ADRs conducted by the FDA and pharmaceutical manufacturers vs the RADAR project...
  30. ncbi request reprint Current issues in rectal cancer chemotherapy
    Mathew Joseph
    Division of Hematology and Oncology, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer J 13:198-203. 2007
    ..Additionally, new agents in the treatment of rectal cancer will be discussed. Finally, the design of 2 current studies incorporating these issues in their trial design will be presented...
  31. ncbi request reprint Adjuvant therapy for stage II colon cancer: prognostic and predictive markers
    Brian Vicuna
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    J Natl Compr Canc Netw 5:927-36. 2007
    ..With the development of the newer therapeutic agents, oxaliplatin and bevacizumab, ongoing trials such as Intergroup E5202 should help determine risk versus benefit of chemotherapy in the adjuvant treatment of stage II colon cancer...
  32. ncbi request reprint Recent and ongoing clinical trials for treating colorectal cancer
    Mary F Mulcahy
    Division of Hematology and Oncology Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Suite 850, 676 North Saint Clair, Chicago, IL 60611, USA
    Expert Opin Investig Drugs 11:871-80. 2002
    ..Ongoing and proposed studies are incorporating the identification of genetic and molecular abnormalities, which may provide prognostic information as well as direct treatment decisions...
  33. ncbi request reprint New agents for colorectal cancer
    Mary E Mulcahy
    Division of Hematology and Oncology Department of Medicine, Feinberg School of Medicine, Northwestern University Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    J Natl Compr Canc Netw 1:125-36. 2003
    ..Studies are now focusing on how best to use the available agents. These new agents and new combinations of agents and of approaches have led and should continue to lead to improved outcomes in the treatment of patients with CRC...
  34. ncbi request reprint Bevacizumab in the treatment of colorectal cancer
    Mary F Mulcahy
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, 676 North Saint Clair, Suite 850, Chicago, IL 60611, USA
    Expert Opin Biol Ther 5:997-1005. 2005
    ..Infrequent severe toxicities have been reported, consisting of arterial thrombosis and gastrointestinal perforations (1.5%). Bevacizumab represents the first angiogenesis modulator that has a proven benefit in cancer therapy...
  35. pmc Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma
    Riad Salem
    Department of Radiology, Section of Interventional Radiology and Division of Interventional Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Gastroenterology 140:497-507.e2. 2011
    ..Radioembolization with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy. We performed a comparative effectiveness analysis of these therapies in patients with HCC...
  36. doi request reprint Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization
    Ahsun Riaz
    Department of Radiology, Northwestern University, Chicago, IL 60611, USA
    Int J Radiat Oncol Biol Phys 79:163-71. 2011
    ..We sought to (1) calculate dose when activity is delivered segmentally assuming uniform and nonuniform distribution and, (2) determine safety and efficacy of this novel technique...
  37. ncbi request reprint Adenocarcinoma arising in rectal duplication cyst: case report and review of the literature
    Anand T Shivnani
    Division of Radiation Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Am Surg 70:1007-9. 2004
    ....
  38. ncbi request reprint Impact of diabetes mellitus on outcomes in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:433-40. 2003
    ..To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer...
  39. pmc Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma
    Ahsun Riaz
    Department of Radiology, Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    JAMA 303:1062-9. 2010
    ..No universally accepted standard exists...
  40. ncbi request reprint Inoperable pancreatic cancer: standard of care
    Kari B Wisinski
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Oncology (Williston Park) 21:1558-64; discussion 1565, 1570-2. 2007
    ..Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge...
  41. ncbi request reprint The assessment and management of cancer treatment-related diarrhea
    Bridget E O'Brien
    Northwestern Medical Faculty Foundation, Northwestern University, Chicago, IL 60611, USA
    Clin Colorectal Cancer 4:375-81; discussion 382-3. 2005
    ..Early recognition and management of diarrhea will be essential to improve control of diarrhea, and in turn will positively impact patients' quality of life...
  42. ncbi request reprint Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer
    Al B Benson
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Clin Adv Hematol Oncol 4:747. 2006
  43. ncbi request reprint Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
    Mace L Rothenberg
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    J Clin Oncol 23:9265-74. 2005
    ..Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha)...
  44. ncbi request reprint The role of molecular markers in predicting response to therapy in patients with colorectal cancer
    Veena Shankaran
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine at Northwestern University, Chicago, Illinois, USA
    Mol Diagn Ther 12:87-98. 2008
    ....
  45. ncbi request reprint Optimal use of the combination of irinotecan and 5-fluorouracil
    Al B Benson
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 30:68-77. 2003
    ..Future directions include the testing of a complex array of new agents and the incorporation of laboratory predictors of survival and response as a component of clinical trial design...
  46. ncbi request reprint Pilot study of gemcitabine (10 mg/m(2) per min) and cisplatin
    Elizabeth Poplin
    Division of Oncology, Department of Medicine, Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, USA
    Cancer Chemother Pharmacol 50:80-3. 2002
    ..In this pilot study, we wished to assess if full-dose gemcitabine when given with cisplatin could be delivered by this more prolonged infusion...
  47. ncbi request reprint Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis
    Laura M Kulik
    Department of Hepatology, Northwestern University, Chicago, IL, USA
    Hepatology 47:71-81. 2008
    ..Further investigation is warranted in patients with main PVT...
  48. doi request reprint 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience
    Thomas K Rhee
    Department of Radiology, Northwestern University, Chicago, IL, USA
    Ann Surg 247:1029-35. 2008
    ....
  49. ncbi request reprint Molecular markers in prognosis of colorectal cancer and prediction of response to treatment
    Boris Pasche
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Best Pract Res Clin Gastroenterol 16:331-45. 2002
    ..The purpose of this chapter is to provide a critical assessment of the usefulness of markers in the prognosis and prediction of response to treatment in colorectal cancer...
  50. pmc Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Elizabeth A Richey
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave, Chicago, IL 60611, USA
    J Clin Oncol 27:4398-405. 2009
    ....
  51. ncbi request reprint Ostomy care: the added considerations for cancer patients
    Bridget O'Brien
    Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    J Support Oncol 3:71-2. 2005
  52. ncbi request reprint Clinical practice. Surveillance strategies after curative treatment of colorectal cancer
    David G Pfister
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 350:2375-82. 2004
  53. doi request reprint The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings
    Polina Khrizman
    Hematology Oncology, Northwestern University, Chicago, IL, USA
    Clin Colorectal Cancer 9:136-43. 2010
    ..It will review available data and will discuss future directions in the GI field...
  54. pmc Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions
    Veena Shankaran
    Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncologist 15:157-67. 2010
    ....
  55. ncbi request reprint Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
    PETER J O'DWYER
    Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA
    J Clin Oncol 25:2313-21. 2007
    ..The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy...
  56. ncbi request reprint Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites
    Patrick G Johnston
    Cancer Research Centre, Department of Oncology, Queen s University Belfast, Belfast, Northern Ireland
    J Clin Oncol 21:815-9. 2003
    ....
  57. doi request reprint Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
    ..Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%...
  58. doi request reprint Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
    Howard L Kaufman
    Columbia University Medical Center, New York, New York 10032, USA
    Clin Cancer Res 14:4843-9. 2008
    ..This study was conducted to assess the effects of systemic chemotherapy on ALVAC-CEA/B7.1-induced T-cell immunity in patients with metastatic colorectal cancer...
  59. doi request reprint Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 72:108-13. 2008
    ..We performed a Phase I trial to test the safety and preliminary efficacy of adding oxaliplatin to standard preoperative chemoradiation therapy for rectal cancer...
  60. ncbi request reprint Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
    A David McCollum
    A D McCollum, R J Mayer, C S Fuchs, Dana Farber Cancer Institute, Boston, MA, USA
    J Natl Cancer Inst 94:1160-7. 2002
    ..In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer...
  61. ncbi request reprint Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer
    John C Marsh
    Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 2:43-50. 2002
    ..This regimen has not shown to be effective in patients who have had prior chemotherapy...
  62. ncbi request reprint Epidermal growth factor receptor-targeted therapy in colorectal cancer
    PETER J O'DWYER
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Semin Oncol 29:10-7. 2002
    ..Preclinical and clinical trials using these new therapeutic modalities appear promising in the treatment of colorectal cancer and are reviewed in this article...
  63. ncbi request reprint Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study
    M Margaret Kemeny
    Cancer Center of Queens, Queens Hospital Center, Jamaica, Queens, NY 11432, USA
    J Clin Oncol 20:1499-505. 2002
    ....
  64. doi request reprint Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
    William F Regine
    Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
    JAMA 299:1019-26. 2008
    ..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil...
  65. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA 90404, USA
    Clin Cancer Res 13:6853s-6s. 2007
    ....
  66. ncbi request reprint American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Al B Benson
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 22:3408-19. 2004
    ....
  67. ncbi request reprint The hope for today--the promise for tomorrow: will oncologists meet the challenge?
    Al B Benson
    J Clin Oncol 25:2156-8. 2007
  68. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  69. ncbi request reprint Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group
    Mary Armanios
    Johns Hopkins University, Baltimore, MD 21205, USA
    J Clin Oncol 22:4495-9. 2004
    ..To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia...
  70. ncbi request reprint Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144
    Stephen R Smalley
    Kansas City Community Clinical Oncology Program CCOP, Kansas City, KS, USA
    J Clin Oncol 24:3542-7. 2006
    ..Adjuvant chemoradiotherapy after or before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. We studied three postoperative fluorouracil (FU) radiochemotherapy regimens...
  71. ncbi request reprint Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  72. ncbi request reprint Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology
    Margaret A Tempero
    J Natl Compr Canc Netw 3:598-626. 2005
  73. ncbi request reprint Colon cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:468-91. 2005
  74. ncbi request reprint NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  75. ncbi request reprint A rose, is a rose, is a rose...or not
    Al B Benson
    J Clin Oncol 22:1773-5. 2004
  76. ncbi request reprint Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:484-95. 2003
    ..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized...
  77. ncbi request reprint Rectal cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:492-508. 2005
  78. pmc Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy
    Lanlan Shen
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:6093-8. 2007
    ..We sought to determine the prognostic significance of CIMP in advanced colorectal cancer patients treated with 5-fluorouracil (5-FU) in an Eastern Cooperative Oncology Group clinical trial...
  79. ncbi request reprint Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  80. ncbi request reprint Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
    Heinz Joseph Lenz
    Department of Medical Oncology, University of Southern California, Los Angeles, California, USA
    Cancer 109:33-40. 2007
    ....
  81. ncbi request reprint Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:648-57. 2004
    ..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
  82. ncbi request reprint Adjuvant therapy for pancreatic cancer: one small step forward
    Al B Benson
    JAMA 297:311-3. 2007
  83. ncbi request reprint Anal canal cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:510-5. 2005
  84. ncbi request reprint Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  85. ncbi request reprint Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline
    Christopher E Desch
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 23:8512-9. 2005
    ..To update the 2000 American Society of Clinical Oncology guideline on colorectal cancer surveillance...
  86. ncbi request reprint Colon cancer
    Paul F Engstrom
    Fox Chase Cancer Center, USA
    J Natl Compr Canc Netw 5:884-925. 2007
  87. ncbi request reprint Neuroendocrine tumors
    Orlo H Clark
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    J Natl Compr Canc Netw 4:102-38. 2006
  88. ncbi request reprint Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296
    Scott Wadler
    Albert Einstein College of Medicine, Bronx, New York, USA
    Cancer J 8:282-6. 2002
    ....
  89. doi request reprint From silos to a critical path of new agent development: a paradigm to revolutionize clinical research
    Al B Benson
    J Clin Oncol 26:1924-5. 2008